drugset / Trial / NCT02172261

Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers

NCT02172261

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective was to investigate whether there was a drug-drug interaction between BI 10773 and glimepiride when co-administered. Therefore, the relative bioavailabilities of BI 10773 and glimepiride were determined when both drugs were given in combination compared to multiple oral doses of BI 10773 once daily alone and a single oral dose of glimepiride given alone.

Timeline

Start
2009-04
Primary completion
2009-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 50 mg Oral
Subject Glimepiride Small molecule 1 mg Oral

Indications

No indication recorded.